Abstract: Systems and methods related to prediction-based resource orchestration in a service fabric are described. An example method for reducing an interruption rate associated with a customer application offered as a collection of services includes predicting one or more quiet time periods associated with each of the service replicas associated with a service fabric, where each of the one or more quiet time periods corresponds to a low value of a predicted load specifying a consumption of a metric by a respective service replica on a given node. The method further includes during the one or more quiet time periods predicted by a trained machine learning model, performing an impact-less failover for one or more of the service replicas by scheduling a move for the one or more service replicas from a first node associated with the service fabric to a second node associated with the service fabric.

Abstract: Described are processes for the manufacture of compounds containing a (S)-4,5-dihydro-1H-pyrazole ring. These processes include a chiral resolution step of an intermediate using selected chiral resolving agents. For example, the chiral resolving agents may be selected from (?)-quinine, (R)-phenethylamine, (S)-phenethylamine, (S)-1-naphthylethy lamine, (R)-(?)-2-amino-3-methyl-1-butanol, (?)-cinchonidine, (?)-spartein, (R)-1-naphthylethy lamine, D-arginine, L-lysine, (S)-(+)-2-pyrrolidinemethanol and(1R,2S)-(+)-cis-1-amino-2-indanol.

Abstract: Biomedical devices such as silicone hydrogels formed from a polymerization product of a mixture comprising (a) a siloxane-containing homopolymer which has only one thio carbonyl thio fragment of a reversible addition fragmentation chain transfer (RAFT) agent; and (b) one or more biomedical device-forming comonomers are disclosed.

Abstract: Biomedical devices such as silicone hydrogels formed from a polymerization product of a mixture comprising (a) a siloxane-containing homopolymer which has only one thio carbonyl thio fragment of a reversible addition fragmentation chain transfer (RAFT) agent; and (b) one or more biomedical device-forming comonomers are disclosed.

Abstract: Biomedical devices such as silicone hydrogels formed from a polymerization product of a mixture comprising (a) a siloxane-containing homopolymer comprising one or more thio carbonyl thio fragments of a reversible addition fragmentation chain transfer (RAFT) agent; and (b) one or more biomedical device-forming monomers are disclosed.

Abstract: Biomedical devices such as silicone hydrogels formed from a polymerization product of a mixture comprising (a) a siloxane-containing homopolymer comprising one or more thio carbonyl thio fragments of a reversible addition fragmentation chain transfer (RAFT) agent; and (b) one or more biomedical device-forming monomers are disclosed.

Abstract: This invention describes the use of amphiphilic multiblock copolymers comprising a hydrophobic segment and a hydrophilic the amphiphilic multiblock copolymer has at least one thio carbonyl thio group capable of participating in a free radical reaction as comonomers in forming ophthalmic devices such as contact lenses, intraocular lenses, corneal implants, etc.

Abstract: The present invention relates to 14- or 15-membered macrolides substituted at the 4? position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.

Abstract: The present invention relates to 14- or 15-membered macrolides substituted at the 4? position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.

Abstract: The present invention relates to 14- or 15-membered macrolides substituted at the 4? position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.

Abstract: The present invention relates to 14- or 15-membered macrolides substituted at the 4? position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.

Abstract: The present invention relates to 14 or 15 membered macrolides substituted at the 4? position of formula (I) and pharmaceutically acceptable salts and solvates thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body

Abstract: The present invention relates to 14- or 15-membered macrolides substituted at the 4? position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.

Abstract: The present invention relates to 14 or 15 membered macrolides substituted at the 4th position of formula (I) and pharmaceutically acceptable salts and solvates thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body.